Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Becton, Dickinson and Company

BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.

BD & Henry Ford Health Tie-Up to Enhance Community Pharmacy Experience

Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristocrats already raising payouts in 2025 at an average rate of 5.19%, nearing last year's pace. 22 Dividend Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.

Best Dividend Aristocrats For October 2025

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Becton Dickinson (BDX) is a Strong Value Stock

FRANKLIN LAKES, N.J. , Sept. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a robotic solution that will enable patients to pick up select prescriptions at their convenience — 24 hours a day, seven days a week.

BD and Henry Ford Health Sign Pharmacy Automation Partnership to Revolutionize Medication Storage and Prescription Delivery

Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research

Fluorescence Cell Market Forecasts USD 6.37 Billion by 2034 at 7.29% CAGR

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Becton, Dickinson and Company (BDX) Stock?

FRANKLIN LAKES, N.J. , Sept. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™ System, a flagship instrument for single-cell multiomics analysis, at Addenbrooke's Hospital of the University of Cambridge, United Kingdom.

BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics

On 9/8/25, Alphabet, Becton, Dickinson, and Rogers Communications will all trade ex-dividend for their respective upcoming dividends. Alphabet will pay its quarterly dividend of $0.21 on 9/15/25, Becton, Dickinson will pay its quarterly dividend of $1.04 on 9/30/25, and Rogers Communications will pay its quarterly dividend of $0.50 on 10/3/25.

Ex-Dividend Reminder: Alphabet, Becton, Dickinson And Rogers

Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Thomas Polen - President, CEO & Chairman Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning, everyone, and welcome to the 2025 Wells Fargo Healthcare Conference.

Becton, Dickinson And Company (BDX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

FRANKLIN LAKES, N.J. , Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE: BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations.

BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.

Best Dividend Aristocrats For September 2025

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued with expected long-term annualized returns of at least 10%, based on Dividend Yield Theory analysis. Recent dividend increases have modestly boosted the group's 2025 dividend growth rate, though it still trails last year's pace.

Best Dividend Kings: August 2025

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings potential.

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

Dividend Growth Outperformance: For over 50 years, dividend growers have delivered market-beating returns with lower volatility. The BTI Example: British American Tobacco went from six years of stagnation to 63% gains in 2025, beating the Mag 7 and Bitcoin—underscoring the power of patience. I've found 11 dividend aristocrats with 70%+ quality scores and 50+% justified 12-month return potential, based on yield, growth, and valuation.

11 Dividend Aristocrats With Excellent Upside Potential In The Next Year

FRANKLIN LAKES, N.J. , Aug. 14, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025 at 8:00 a.m.

BD to Present at Wells Fargo 2025 Healthcare Conference

Here's Why Becton Dickinson (BDX) is a Strong Growth Stock

We remain patient and opportunistic, raising cash to capitalize on future volatility and focusing on stocks meeting our 10 Principles of Value Investing™. We initiated a position in Applied Materials, leveraging semiconductor industry weakness, and see secular tailwinds and potential for multiple expansion to the low $300s. Sensient Technologies delivered strong results on natural color demand, but with valuation now higher, the risk-reward is less compelling than at initial purchase.

Heartland's 3 Tactical Q2 Moves: Trimming Risk, Harvesting Losses, And Raising Cash

Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term

Real-time stock quote and overview for BDX